期刊文献+

小密低密度脂蛋白与冠状动脉损伤严重程度的关系 被引量:1

下载PDF
导出
摘要 目的:探讨冠心病患者小密低密度脂蛋白(small dense low-density lipoprotein,sLDL)水平与冠状动脉损伤严重程度的关系。方法:将276例接受冠状动脉造影检查的患者根据是否有主要冠状动脉或(和)其主要分支直径狭窄≥50%的情况分为对照组及冠心病组,计算所有受试者的冠状动脉损伤严重程度积分(Gensini积分),并测定其血浆中sLDL在低密度脂蛋白(low density lipoprotein,LDL)中所占的百分率。结果:冠心病组血浆sLDL水平明显高于对照组(P<0.01),sLDL与Gensini积分呈正相关(r=0.423,P<0.01)。结论:sLDL是冠心病发病的一个独立危险因素,并且与冠状动脉损伤严重程度呈正相关。
作者 薛明 秦勤
出处 《实用医学杂志》 CAS 北大核心 2011年第17期3157-3159,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献6

  • 1王勇,赵熹.新疆青年冠心病临床特点分析[J].实用医学杂志,2010,26(2):325-325. 被引量:2
  • 2王旭红,寇俊杰,张健.瑞舒伐他汀治疗血脂异常的疗效观察[J].实用医学杂志,2009,25(9):1498-1499. 被引量:30
  • 3Ai M, Otokozawa S, Asztalos B F, et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham offspring study [J]. Clin Chem, 2010,56(6): 967-976.
  • 4Berneis K, Rizzo M, Berthold H K, et al. Ezetimibe alone or in combination with simvastatin increase small dense lowdensity lipoprotein in healthy men: a randomized trial [ J]. Euro Heart J, 2010,31(13) : 1633-1639.
  • 5Rizzo M, Berneis K, Spina G A, et al. Quantitative and qualitative effects of rosuvastatin on LDL-cholesteml: what is the clinical significance? [J]. Clinic Pract, 2009,63 (3): 478 -485.
  • 6Munivappa R, Lee S, Chen H, et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage [J]. Am J Physiol Endocrinol Metab, 2008,294 ( 1 ) : E 15-26.

二级参考文献18

  • 1Slamler J , Wentworth D, Neaton J D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) [J]. JAMA, 1986,256 (20) : 2823 -2828.
  • 2Castelli W P, Garrison R J, Wilson PwF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framing ham Study [ J ]. JAMA, 1986, 256(20) : 2835-2838.
  • 3Frick M H, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dislipidemia. Safetyof treatment, chages in risk factors, and incidence of coronary heart disease [J]. N Engl J Med, 1987,317 (20) : 1237-1245.
  • 4Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel Ⅱ) [J]. JAMA, 1993, 269(23):3015-3023.
  • 5Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in Adults. The Expert Panel [J]. Arch Intern Med, 1998, 148 (1): 36-69.
  • 6Sniderman A D, Pedersen T, Kjekshus J. Putting low density lipoproteins at a center stage in atherogenesis [J]. Am J Cardiol, 1997, 79( 1 ) :64-67.
  • 7Kaplan I V, Levinson S S. Apolipoprotein snd related testing as markersfor coronary disease [J]. Lab Med Int, 1998, 15 ( 1 ) : 12 - 14.
  • 8Michaeld, Patricke, Evanas, et al. Comparison of effects on lowdensity lipoprotein and cholesterol with rosuvastatin versusatorvastatin in patients with type Ⅱ a or Ⅱ b hypercholesterolemia [J]. J Am Cardiol, 2002,89(2) : 268-275.
  • 9Shwartz G G, Bolognese M A, Tremblay B P, et al. Efficacy and safety of rosuvastatin and atorvastin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial [ J ]. Am Heart J, 2004,148 ( 1 ) : e4.
  • 10Olsson A G, Istad H, Luurila, et al. Effects of rosuvastatin and atrovastatin compared over 52 weeks of treatment in patients with hypercholesterolemia [ J ]. Am Heart J, 2002,144 (6) : 1044-1051.

共引文献30

同被引文献8

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部